Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.53 |
| ▸ | CDK2 | P24941 | 14/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 14/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22522948 | 0.91 | SMN1; SMN2 (0.56) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523043 | 0.91 | SMN1; SMN2 (0.56) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22522971 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL24246502 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20883077 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20883052 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523005 | 0.85 | CCNE1 (0.54) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523008 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523021 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20877548 | 0.84 | CCNE1 (0.50) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | SMN1; SMN2 88/4885CCNE1 3461/4885CDK2 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.